Niraparib belongs to several generations of targeted drugs

Niraparib (Niraparib) is a PARP inhibitor and a new generation of targeted drugs that has been widely used in the treatment of gynecological tumors such as ovarian cancer, fallopian tube cancer and primary peritoneal cancer. As a representative of several generations of targeted drugs, niraparib has some special advantages. Niraparib inhibits the DNA damage repair pathway by acting on the PARP enzyme in tumor cells, thereby interfering with the survival and proliferation of tumor cells, thereby achieving the purpose of anti-tumor. Niraparib is an oral drug with the advantages of convenience, high efficiency, and low toxicity. Most importantly, niraparib is effective in treating ovarian cancer and other gynecological tumors, especially for patients with BRCA gene mutations.